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INDAPAMIDE HEMIHYDRATE, a non-
thiazide diuretic, is available in Australia
in a 2.5 mg immediate-release (IR)
formulation and a 1.5 mg sustained-
release (SR) formulation. In July 2000,
when it became known that supply of
500 mg chlorothiazide was to be discon-
tinued, the 2.5 mg IR preparation of
indapamide began to be promoted as a
substitute for chlorothiazide. Recently, a
combination product (perindopril erbu-
mine and indapamide hemihydrate) has
also been registered.
Clinically significant hyponatraemia
has been attributed to indapamide as
well as to the thiazide diuretics. The
symptoms of hyponatraemia may begin
with nausea and malaise, and progress
to headache, lethargy, confusion and
obtundation. Stupor, seizures and coma
may occur if the serum concentration
falls acutely below 120 mmol/L, or
decreases rapidly.1 There is also a risk of
pontine myelinolysis if the hyponatrae-
mia is treated inappropriately.2 Hypo-
kalaemia may result in muscle weakness
and cardiac arrhythmias; symptoms
generally only appear with severe
hypokalaemia (less than 2.5 mmol/L).3
We undertook this study to review the
reporting of indapamide-associated
electrolyte disturbances in Australia. We
used chlorothiazide and the combina-
tion diuretic hydrochlorothiazide
(50 mg) and amiloride hydrochloride
(5 mg) as comparator drugs.
METHODS
1.Methods
The information analysed was obtained
from the computerised records of Aus-
tralian adverse drug reaction reports held
by the Adverse Drug Reactions Advisory
Committee (ADRAC). Chlorothiazide
was used in Australia before the estab-
lishment of the computerised database in
November 1972, and only reports
received after that date were examined.
The first report for the hydrochloro-
thiazide and amiloride combination was
submitted in January 1975 and the first
for indapamide in August 1984. We only
considered reports in which the diuretic
was the sole suspected drug.
Detailed computerised summaries of
each report were retrieved, and checked
against the original reports to safeguard
against error during data entry. The five
most commonly reported adverse reac-
tions for each of the drugs were
identified using the preferred terms
from the World Health Organization
Adverse Reaction Terminology.4 There
was some overlap between drugs, result-
ing in our analysing the 11 reactions
shown in Box 1. Demographic informa-
tion was extracted from each report
(such details were not available in only a
small number of reports) and other
symptoms and signs recorded in the
reports were noted.
The Royal College of Pathologists of
Australasia gives the following reference
intervals:5 
■ serum sodium, 135–145 mmol/L; 
■ serum potassium, 3.8–4.9 mmol/L;
and
■ plasma potassium, 3.4–4.5 mmol/L. 
Reports to ADRAC describing elec-
trolyte disturbances do not always
include laboratory results or reference
intervals. For our primary analysis,
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ABSTRACT
Objectives:  To review Australian adverse drug reaction reports describing 
hyponatraemia and hypokalaemia attributed to indapamide and compare the 
characteristics of the patients with those in Australian reports implicating two other 
diuretic products (hydrochlorothiazide and amiloride hydrochloride; chlorothiazide).
Design:  Descriptive analysis using reports from the database of the Adverse Drug 
Reactions Advisory Committee (ADRAC).
Main outcome measures:  Numbers of reports of hyponatraemia and 
hypokalaemia; proportion of such reports in total reports of adverse reactions to 
each drug; severity of electrolyte disturbances.
Results:  Between August 1984 and September 2000, 84 Australian reports of 
hyponatraemia and 87 reports of hypokalaemia, in which indapamide was the sole 
suspected drug, were submitted to ADRAC. Most reports involved an indapamide 
dose of 2.5 mg daily. There was a significantly greater proportion of reports of 
hyponatraemia with indapamide and with the hydrochlorothiazide and amiloride 
combination than with chlorothiazide; hypokalaemia was significantly more common 
for indapamide than for the other two drugs. Of the 87 reports of hypokalaemia with 
indapamide, 35 patients also had hyponatraemia. For all three drugs, at least 80% of 
reports of hyponatraemia were in people aged 65 or over, and electrolyte 
disturbance was most commonly reported in elderly women.
Conclusions:  Hyponatraemia and hypokalaemia have been described in 20.9% 
and 21.7%, respectively, of reports to ADRAC in which indapamide was the sole 
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suspected drug. The electrolyte disturbances can be severe.
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reports describing hyponatraemia or
hypokalaemia were accepted at face
value.
Statistical analysis
The number of reports of each reaction
as a proportion of total reports for each
of the three drug products was calcu-
lated, together with the 95% confidence
intervals. Two proportions were consid-
ered to be statistically significantly
different if their 95% confidence inter-
vals did not overlap.
RESULTS
1.Results
Usage data were obtained for the three
diuretics (Mr Peter McManus, Pharma-
ceutical Benefits Branch, personal com-
munication) by a method in which
Pharmaceutical Benefits Scheme (PBS)
data and results of a survey of pharma-
cies are combined.6 Box 2 shows that,
for the financial years 1989/90 to 1997/
98, use of indapamide increased at a
time when use of the other two drugs
decreased markedly.
As shown in Box 1, 136 reports
involving chlorothiazide, 390 involving
the hydrochlorothiazide and amiloride
combination and 401 involving indapa-
mide had been received to 30 Septem-
ber 2000. Both the hydrochlorothiazide
and amiloride combination and indapa-
mide had significantly higher propor-
tions of reports of hyponatraemia than
chlorothiazide. Indapamide had a signif-
icantly higher proportion of reports of
hypokalaemia than the other two drugs.
For all three drugs, at least 80% of
reports of hyponatraemia were in people
aged 65 or over (chlorothiazide, 2/2
[100%]; hydrochlorothiazide and ami-
loride, 52/63 [83%]; indapamide, 69/84
[82%]), and at least 78% of patients
were female (chlorothiazide, 2/2
[100%]; hydrochlorothiazide and ami-
loride, 49/63 [78%]; indapamide, 67/84
[80%]). For indapamide, most patients
with hypokalaemia were aged 65 or over
(53/87 [61%]), and most were female
(61/87 [70%]).
For all three drugs, at least 50% of
reports described patients with serum
sodium concentrations  120 mmol/L.
In the 84 reports with indapamide, as
well as hyponatraemia symptoms men-
tioned included nausea (15 reports),
confusion (13), vomiting (11), dizziness
(9), anorexia (8), fatigue (5), malaise
(4), syncope (4), somnolence (4),
headache (2) and convulsions (2). One
or more of these signs and symptoms
was mentioned in 39 of the 84 reports.
At least 72 of the 84 reports of
hyponatraemia with indapamide related
to the use of 2.5 mg IR daily (dose
explicitly stated in 53; stated as one
tablet daily for a brand available only as
2.5 mg IR or reported before the 1.5 mg
SR formulation was marketed in 19).
Only two reports explicitly stated
another daily dose. At least 77 of 87
reports of hypokalaemia with indapa-
mide related to use of 2.5 mg IR tablets
(dose explicitly stated in 59; stated as
one tablet daily and reported when only
2.5 mg available in 18). Only one report
explicitly stated another daily dose.
Of the 87 reports of hypokalaemia
with indapamide, 35 patients also had
hyponatraemia. A serum potassium
concentration was included in 67 of the
87 reports (10 [15%], < 2.5 mmol/L;
34 [51%], 2.5 to < 3.0 mmol/L; 23
[34%], 3.0–3.5 mmol/L). Six of the 10
2: Estimated Australian usage of 
three diuretics, for the financial 
years 1989/90 to 1997/98
1: Numbers and proportions (with 95% confidence intervals) of commonly reported suspected adverse reactions 
in which the diuretic was the sole suspected drug 
Number of reports Chlorothiazide
Hydrochlorothiazide 
with amiloride Indapamide
Total 427 763 644
Diuretic sole suspected drug 136 390 401
Hyponatraemia 2 (1.5%; 0.2%–5.2%) 63 (16.2%; 12.6%–20.2%) 84 (20.9%; 17.1%–25.3%)
Hypokalaemia 6 (4.4%; 1.6%–9.4%) 25 (6.4%; 4.2%–9.3%) 87 (21.7%; 17.8%–26.1%)
Nausea 5 (3.7%; 1.2%–8.4%) 31 (7.9%; 5.5%–11.1%) 51 (12.7%; 9.6%–16.4%)
Pruritus 15 (11.0%; 6.3%–17.5%) 28 (7.2%; 4.8%–10.2%) 25 (6.2%; 4.1%–9.1%)
Fatigue 2 (1.5%; 0.2%–5.2%) 15 (3.8%; 2.2%–6.3%) 28 (7.0%; 4.7%–9.9%)
Dizziness 5 (3.7%; 1.2%–8.4%) 23 (5.9%; 3.8%–8.7%) 31 (7.7%; 5.3%–10.8%)
Headache 5 (3.7%; 1.2%–8.4%) 11 (2.8%; 1.4%–5.0%) 29 (7.2%; 4.9%–10.2%)
Photosensitivity reaction 18 (13.2%; 8.0%–20.1%) 79 (20.3%; 16.4%–24.6%) 8 (2.0%; 0.9%–3.9%)
Rash (not otherwise specified) 10 (7.4%; 3.6%–13.1%) 16 (4.1%; 2.4%–6.6%) 19 (4.7%; 2.9%–7.3%)
Maculopapular rash 9 (6.6%; 3.1%–12.2%) 24 (6.2%; 4.0%–9.0%) 23 (5.7%; 3.7%–8.5%)
Erythematous rash 11 (8.1%; 4.1%–14.0%) 14 (3.6%; 2.0%–5.9%) 13 (3.2%; 1.7%–5.5%)
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reports with a serum potassium concen-
tration < 2.5 mmol/L mentioned other
symptoms, including confusion, convul-




Indapamide has been implicated as a
cause of severe hyponatraemia in a small
number of case reports,7 and our
findings support this. It is striking that
there was a greater proportion of
Australian reports of hyponatraemia
with indapamide than with the hydro-
chlorothiazide and amiloride combina-
tion. Further, this proportion is many
times greater than that for chloro-
thiazide. The reports show that indapa-
mide-associated hyponatraemia resem-
bles that caused by hydrochlorothiazide
with amiloride in that it can be severe,
and is reported predominantly in elderly
women.8
Voluntary reporting systems do not
provide a basis for calculating incidence
or robust estimates of risk. The experi-
ence reported here relates almost solely
to 2.5 mg IR indapamide tablets, the
use of which has increased in recent
years. Whether similar electrolyte dis-
turbances will be observed with 1.5 mg
SR indapamide tablets, subsidised on
the PBS since 1 November 2001,
requires further postmarketing surveil-
lance.
Increasing use of indapamide in place
of chlorothiazide will expose more
patients to the risk of hyponatraemia.
Changes in the conscious or mental
states in patients, especially elderly
women, taking indapamide should
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BOOK REVIEW
Learning from literature
Medicine and literature: The doctor’s companion
to the classics. John Salinsky. Abingdon, UK:
Radcliffe Medical Press, 2002 (vi + 236 pp,
$53.50). ISBN 1 85775 535 9.
IT IS NOT EASY, in a busy medical life,
to find time to read literature. Spare
time is devoted to reading medical
journals and newspapers to try and
keep abreast of medical developments
and world events. Occasionally, we see
a movie or read something frivolous,
but serious books often remain
unfinished on the bedside table.
John Salinsky is a general practi-
tioner from Middlesex, UK, who uses
classical literature in teaching his
registrars. He is responsible for the
“Medicine and literature” column in
the journal Education for primary care,
and the present work includes 17
contributions from this column. Most
pieces are by Salinsky himself, and he
writes clearly and entertainingly, mak-
ing it a joy to read. 
Salinksy’s argument is that the
classics are classics not just because of
the quality of the writing, but because
they describe human relationships in a
manner that is both engaging and
timeless. From these works of literature
we can learn much about human
behaviour, its strengths and frailties,
and become better at the “art” of
medicine.
Some of the writers he talks about
are doctors, like Mikhail Bulgakov, or
were the sons of doctors, like Dos-
toyevsky or Flaubert. Others tell stories
in which doctors play central roles, like
Kafka, whose A country doctor contains
the wonderful line, “To write prescrip-
tions is easy, but to come to an
understanding with people is hard”.
Salinsky’s purpose is not to introduce
us to stories by or about doctors, but
rather to stories that contain characters
that we will recognise in our practices.
Our familiarity with and love of these
personalities will increase our under-
standing of those of our patients who
are excessively garrulous, who seem
unable to take control of their lives or
whose characters seem inherently
flawed.
If you already love good literature,
this book will delight and inform you.
If you have forgotten how much
pleasure can be obtained from a great
story, it may motivate you to return to
a world that provides a wealth of
entertainment and stimulation. Almost
everybody will be introduced to some-
thing unfamiliar, but at just over $53 it
is probably best borrowed from the
library rather than added to one’s own.
John Ward
Director
Aged Care and
Rehabilitation Service
Hunter Health
Newcastle, NSW
